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Abstract
Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess and 
improve due to variations in definitions of the problem and the heterogeneous methods of 
medication review and reduction. The purpose of this review is to summarize evidence regarding 
the prevalence and impact of polypharmacy in geriatric oncology patients and to provide 
recommendations for assessment and management. Polypharmacy has somewhat variably been 
incorporated into geriatric assessment studies in geriatric oncology, and polypharmacy has not 
been consistently evaluated as a predictor of negative outcomes in patients with cancer. Once 
screened, interventions for polypharmacy are even more uncertain. There is a great need to create 
standardized interventions to improve polypharmacy in geriatrics, and particularly in geriatric 
oncology. The process of deprescribing is aimed at reducing medications for which real or 
potential harm outweighs benefit, and there are numerous methods to determine which 
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medications are candidates for deprescribing. However, deprescribing approaches have not been 
evaluated in older patients with cancer. Ultimately, methods to identify polypharmacy will need to 
be clearly defined and validated, and interventions to improve medication use will need to be 
based on clearly defined and standardized methods.
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INTRODUCTION
Polypharmacy is often described as a prescribing challenge, particularly in the care of older 
patients with cancer and multiple comorbid conditions that interact in complex ways. There 
are various definitions of polypharmacy, making it challenging to understand the scope and 
impact of the problem. A 2008 review suggested that there are 24 distinct definitions of 
polypharmacy in general use, encompassing concepts ranging from unnecessary or 
inappropriate medication use to the use of excessive numbers of medications.1 The lack of a 
consistent definition and understanding of polypharmacy creates confusion for clinicians, 
educators, and researchers.2
While the use of many medications may be a good practice for the treatment of many 
chronic conditions, polypharmacy in the context of care of the older patient generally refers 
to inappropriate polypharmacy, focusing on the negative aspects of medication use. Taking 
an increasing number of medications, using medications that are not indicated for existing 
medical conditions, being exposed to drug-drug interactions, and taking medications that are 
high risk and/or low benefit (so-called inappropriate medications) are all potential negative 
aspects of polypharmacy.3 Among the other negative effects of polypharmacy are increased 
risk of adverse drug reactions, functional decline and falls, delirium and cognitive 
impairment, and in some studies, increased risk of hospitalization, healthcare utilization, and 
mortality, and even underprescribing.4-7 The more medications a patient is taking, the more 
likely a patient is to have an adverse drug event, experience a drug-drug interaction, to take a 
potentially inappropriate medication, or to be nonadherent to one of the medications.8 
However, as demonstrated in recent cohort studies of middle-aged and older adults, 
polypharmacy may not always be inappropriate or indicative of poor quality care, 
particularly in chronic conditions in which multiple medications are required to maintain 
stable disease control, such as cardiovascular disease.9, 10
The simplest and most conventional definitions for polypharmacy are those based on the 
number of medications a patient is taking. When assessing for polypharmacy, a review must 
include an assessment of non-prescribed medications as well as herbal medicines and 
supplements. The use of 5 or more medications regularly has been a frequently used 
definition for polypharmacy. The advantage of such a definition is the replicability in 
research settings and ease of use in clinical practice when screening patients for 
polypharmacy.11 However, the disadvantage of applying such a definition in clinical settings 
is that simple medication number disregards the harmful or beneficial aspects of each 
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medication. Using an absolute number of medications to define polypharmacy does not 
account for a clinician's determination that polypharmacy may be appropriate in some 
instances, when making individualized prescribing decisions. This is particularly the case for 
patients with multimorbidity in whom multiple treatments have clear benefits. While some 
have defined “excessive polypharmacy” as a very high number of medications (such as 10 or 
more regular medications), this definition may have excellent specificity but inadequate 
sensitivity to apply as a screening tool for harmful medication use.12 Taking 5 or more 
regular medications has been associated with falls, disability, and frailty in general geriatric 
populations and in geriatric oncology, and thus has some justification as a reasonable cut-
point for polypharmacy based on the association with adverse outcomes in older 
patients.13, 14 For example, the sensitivity and specificity for 5 or more medications and the 
risk of falls is 75.7% and 44.5%, respectively; at a cut-point of 10 or more medications, the 
sensitivity is 24.3% and specificity is 85.5%.14
The use of medications and the presence of polypharmacy are on the rise in the general 
population. In the United States, 90% of adults 65 and older participating in the National 
Health and Nutrition Examination Survey in 2011-2012 reported taking at least one 
prescription in the prior 30 days, and 39% reported using 5 or more prescription drugs.15 
Based on population registry data from Tayside, Scotland, 22.1% of all persons used 5 or 
more drugs, and 24.0% of people 80 years and older were dispensed 10 or more drugs in 
2010.16 An additional contributor to polypharmacy is the use of complementary and 
alternative medicine, which is highly prevalent in many populations, including older patients 
with cancer. Such medications contribute to the overall pill burden, cost, nonadherence to 
conventional medications, and risk of drug-drug and drug-disease interactions.17
Older patients with cancer are potentially at a higher risk of polypharmacy. Geriatric 
oncology patients have a high burden of comorbidity, geriatric conditions, and disability, and 
are likely to use multiple medications and to be more susceptible to adverse effects of 
medications.18 Many may already meet the criteria for polypharmacy prior to the initiation 
of cancer chemotherapy and supportive care therapies. Cancer-related therapy also adds to 
the prevalence of polypharmacy because of the increased pill burden and regimen 
complexity, all of which can lead to compromised cancer management plans, such as 
treatment delays or premature treatment discontinuation due to toxicity or adverse drug 
events. Furthermore, in patients with advanced cancer near the end of life, as goals of care 
change to more palliative treatment, additional medications are added to control symptoms, 
while few medications for comorbid conditions are stopped.19 It is uncertain whether the 
geriatric oncology population is uniquely susceptible to polypharmacy, and whether specific 
interventions need to be designed for this population. The purpose of this narrative review is 
to summarize evidence regarding the prevalence and impact of polypharmacy and potentially 
inappropriate medicine use in geriatric oncology patients and to provide recommendations 
for assessment and management.
POLYPHARMACY AND OUTCOMES IN CANCER
Several studies have evaluated the prevalence of polypharmacy in older patients with cancer. 
Depending on the definition of polypharmacy, 11% to 96% of older patients with cancer 
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were exposed to polypharmacy.14, 20-26 Nightingale and colleagues found a prevalence of 
84% for polypharmacy, which includes 43% of patients who met criteria for excessive 
polypharmacy, or 10 or more medications.24 The mean number of medications was 9.23 and 
this was prior to anticancer therapy initiation for most of the patients in the cohort.24 Other 
studies have found that older patients with cancer take a median number of medications of 5 
to 9.1.14, 25 In advanced cancer, patients take more medications, likely because additional 
drugs are added for supportive care.27 In one chart review of 100 patients with advanced 
cancer, 95% had polypharmacy in the week before death.28 In oncology settings, the 
presence of polypharmacy has been associated with higher numbers of comorbidities, 
increased use of inappropriate medications, worse performance status, frailty syndrome, 
poor physical function and poor survival.24, 29, 30
Several studies in geriatric oncology that have looked at multiple risk factors for adverse 
outcomes have identified the effect of polypharmacy (Table 1). As defined by medication 
number, polypharmacy has been associated with postoperative complications and length of 
stay.31, 32 Increased medication number has also been associated with chemotoxicity in 
some studies, but not consistently.33, 34 Polypharmacy was not associated with treatment 
decisions in one study,35 but was associated with an increased likelihood of receiving non-
surgical treatment in another study.36 In addition, many studies have found an association 
with polypharmacy and adverse geriatric-specific outcomes. Medication number has been 
associated with physical function, frailty, and delirium in studies including geriatric 
oncology patients.29, 37, 38 A recently published meta-analysis of data from three phase II/III 
studies in ovarian cancer found that polypharmacy was associated with overall grade III/IV 
toxicity, hematological and nonhematological toxicities, but not associated with overall 
survival.39
While there are few studies regarding outcomes, the existing evidence suggests that an 
increased number of medications used in geriatric patients with cancer could increase the 
risk of complications, chemotoxicity, and increases the risk of functional decline. However, 
most existing studies have evaluated polypharmacy as a covariate or risk factor as part of a 
larger exploration of many potential risk factors for adverse outcome. Ultimately, 
implementing polypharmacy screening and intervention as part of routine practice will 
require studies specifically designed to examine the impact of polypharmacy on outcomes in 
older patients with cancer.
POTENTIALLY INAPPROPRIATE MEDICATION USE
Potentially inappropriate medications (PIMs) are largely referred to as medications lacking 
evidence-based indications, medications with treatment risks that may outweigh their 
benefits, medications that are significantly associated with adverse drug reactions, and those 
that may potentially interact with other medications or other diseases.40 There have been a 
few specific criteria developed for identification of PIMs, including the Beers criteria and 
Screening Tool for Older People's Prescriptions (STOPP). The Beers criteria was originally 
developed in 1991 as a list of drugs to avoid in older patients residing in nursing homes and 
has since been updated for older patients 65 and older and revised multiple times by expert 
panels, most recently in 2015. It is a list of more than 110 potentially problematic 
Sharma et al. Page 4
J Geriatr Oncol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
medications to avoid and more than 60 drug-disease combinations to avoid in older 
people.41 The STOPP criteria is a list of 80 indicators for appropriate prescribing, including 
drugs and doses to avoid as well as drug-disease combinations to avoid. STOPP was 
developed in 2008 and updated in 2015.42 Another tool to identify inappropriate medication 
use is the Medication Appropriateness Index (MAI),43 a list of 10 indicators for prescribing 
that are applied to each medication on a patient's list. This tool is useful to identify factors 
like drugs lacking indication, lacking effectiveness, or potentially increasing the risk of 
harm. The National Comprehensive Cancer Network (NCCN) Older Adult Oncology 
Guideline refers to the MAI,44 however, the MAI may be time-consuming to administer, 
cumbersome for use in clinical settings, must be performed by a skilled clinician with 
training, and does not address underprescribing.45 The NCCN guidelines also present a list 
of specific medications which may be considered of particular concern to the geriatric 
oncology population including sedatives, first generation anti-histamines and anti-emetic 
drugs.44
In the general geriatric population, 12%-63% are exposed to PIMs, based on either the Beers 
or STOPP criteria.46 Most studies evaluating PIMs in patients with cancer have used the 
Beers criteria.20, 22, 23, 47-49 To date, one study has evaluated the prevalence of PIMs in 
patients with cancer using both the Beers and the STOPP criteria in a senior adult oncology 
ambulatory center in the US.24 The overall prevalence of PIMs was 51%, and was 38% 
according to STOPP criteria and 40% according to the 2012 Beers criteria.24
OUTCOMES ASSOCIATED WITH POTENTIALLY INAPPROPRIATE MEDICATION USE
Very few studies have evaluated whether the use of inappropriate medications is associated 
with adverse outcomes in geriatric oncology. In a study of 414 older patients in the general 
population, the presence of both PIMs and polypharmacy combined had a statistically 
significant positive correlation to increased hospital readmissions. PIM use alone, however, 
was not found to be significantly related to readmissions.50 In a secondary analysis of a 
prospective study of factors related to chemotherapy-related adverse events in 7 academic 
medical centers, there was no association found between either polypharmacy or PIM use 
and chemotherapy toxicity or hospitalization.26 Another study evaluating the impact of PIMs 
on outcomes in patients with breast cancer receiving chemotherapy found no association 
between PIM use and the composite outcome of emergency room visits, hospitalization or 
death in 6 months.51
Despite the potential harms of PIMs, observational studies of emergency room visits and 
hospitalizations due to adverse drug reactions (ADRs) have found that most of the 
medication-related harm in older persons is not due to PIMs, but is in fact due to common 
classes of medications not considered inappropriate, including anticoagulants, opioids, 
antiplatelet agents, oral hypoglycemic drugs, insulin, and antiarrhythmic agents.52 However, 
in the same secondary analysis of chemotherapy-related adverse events that found no 
association with PIMs, there was no association between these 6 high risk medication 
classes and adverse outcomes.26 There are a few possibilities for the lack of association 
between PIM use and adverse outcomes in geriatric oncology: 1) there are too few studies to 
date to show an association, and the studies that have been conducted have included 
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heterogeneous populations with early stage and advanced cancer patients; 2) it is possible 
that no association between PIMs and harm exists in geriatric oncology; 3) several 
medications considered to be PIMs are also necessary supportive oncology drugs, and may 
actually mitigate harm in older patients. (NCCN) Additionally, PIM criteria may be 
inapplicable to the end of life oncology population, when preventative medications might be 
considered inappropriate but PIMs (e.g., benzodiazepines) might be appropriate and 
recommended.53
ADDRESSING POLYPHARMACY AS PART OF GERIATRIC ASSESSMENT
A strategy to provide more appropriate, safe medication use in older patients with cancer 
may need to go beyond simple medication number, PIMs, and high risk medications to 
include a comprehensive evaluation of medication use and risk factors for ADRs. The 
medication use process comprises a series of stages including prescribing, communicating 
medication orders, dispensing, administering and monitoring. Because of this multi-stage 
process, adequate patient-provider consultation time is needed to conduct comprehensive 
medication assessments in order to identify all medication related problems. This 
comprehensive medication assessment should be done periodically, especially with the 
initiation or modification of the patient's oncologic management or when there are changes 
in disease management, changes in clinical condition and/or during transitions of care. 
During the visit, the provider should confirm medication indication (e.g. medication-
condition matching), dosage (e.g. dosages appropriate for renal and/or liver function), 
duration, assess for drug duplication, drug-drug-, drug-disease interactions and adverse 
effects; in addition, the patient's ability to read medication label directions and to manage 
medications in an organized manner should be assessed. The provider should not only 
consider the pharmacological properties of the medications, but should also consider the 
patient's comorbidities, cancer prognosis, cognitive and functional status as well as social, 
cultural and economic factors. In this way, the prescribing process encompasses the patient's 
goals of care coupled with maintaining quality of life. A comprehensive medication review 
is considered to be an integral part of the geriatric oncology assessment based on the NCCN 
Older Adult Oncology guidelines.44 The guidelines recommend a comprehensive medication 
assessment, which includes a thorough review of patients’ medications with subsequent 
discontinuation of any nonessential medications and evaluation for drug interactions, 
adverse effects, and patient adherence. Geriatric assessment (GA) is a compilation of various 
validated tools to assess multiple domains in older adults and has been shown in prior 
studies to influence decision-making and predict outcomes such as hospitalization and 
treatment complications in older patients with cancer.35, 54 While the domains of GA include 
a comprehensive assessment of functional status, nutrition, comorbidities, cognition, mental 
health, and social supports, a clear method for the assessment of polypharmacy has not been 
established.
In recent years, an increasing number of studies have incorporated the use of GA in older 
adults with cancer.35, 36, 55 However, polypharmacy was not consistently included as part of 
the GA, which may be due to studies showing mixed results in the correlation between 
polypharmacy and various clinical outcomes, compared to strong correlations noted in other 
GA domains such as comorbidities, functional and nutritional status.33, 56-59 For studies that 
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did include medication assessment, the data was often analyzed and presented as number of 
medications. For example, Joly at al. identified that 43% of older patients aged 65 or above 
with normal Karnofsky performance status (80%-100%) reported taking 9 or more 
medications.60 Some studies further characterized polypharmacy but the definition varies, 
with the most common definition being the concurrent use of ≥ 5 medications.35, 36, 55
When polypharmacy is detected from GA, it is unclear whether interventions aimed at 
reducing medication number are of benefit. Further, many recommended interventions made 
through GA may not have adequate uptake by oncologists. Selected studies published since 
2010 assessing polypharmacy and associated interventions are shown in Table 2. In the 
ELCAPA study, geriatricians proposed to have the prescribed medication changed in 31% of 
patients based on GA results but the percentage of uptake from the proposed medication 
intervention as well as the benefits of the intervention were not reported.35 In a study by 
Kalsi et al, GA interventions were shown to improve chemotherapy tolerance in older 
patients aged 70 or above undergoing chemotherapy.61 In this population, 19% received 
intervention to reduce unnecessary medications such as adjustment of anti-hypertensive 
medications in over or undertreated patients. These interventions, however, vary across the 
various studies and were not clearly defined. In addition, while different definitions of 
polypharmacy account for variation in different studies, differences in the way medication 
use is actually assessed may lead to significant variation in prevalence and impact on 
outcomes.
DEPRESCRIBING AS A POTENTIAL INTERVENTION FOR POLYPHARMACY
Deprescribing is defined as the “systematic process of identifying and discontinuing drugs in 
instances in which existing or potential harms outweigh existing or potential benefits within 
the context of an individual patient's care goals, current level of functioning, life expectancy, 
values, and preferences.”62 While few studies have evaluated the positive outcomes of 
deprescribing, several trials have evaluated the potential negative consequences of stopping 
medications, including exacerbation of the underlying disease as well as drug withdrawal 
syndromes.63 A systematic review of drug withdrawal trials found that the vast majority of 
medications could be safely stopped without adverse events, with careful attention to slower 
withdrawal and close monitoring when stopping cardiovascular drugs and psychotropic 
agents.63 Studies evaluating the positive effects of deprescribing have shown a reduction in 
overall medication number, reduction in the number of inappropriate medications, reduction 
in hospital length of stay, association with global improvements in health, and improvements 
or slower declines in quality of life.62 No studies have been specific to geriatric oncology 
patients, and thus, the benefits and harms of deprescribing in geriatric oncology are 
unknown.
Patients who are prescribed multiple drugs, who take potentially inappropriate medications 
(PIMs), and who have changing goals of care are among the candidates for careful 
medication review with a consideration of deprescribing where appropriate. The process of 
deprescribing has been described in five steps (see Box).62 Some of the steps may seem 
more straightforward and feasible in geriatric oncology. The ability to identify those drugs 
that are high risk/low benefit and to prioritize their discontinuation remains an area in which 
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further research is greatly needed, both in geriatric oncology and in general geriatric 
populations.
Although deprescribing is a possible intervention for older patients with cancer who have 
polypharmacy, the question remains who should lead this intervention among a team that 
may consist of a geriatrician, oncologist, pharmacist, and primary care provider. Barriers to 
accomplishing a deprescribing intervention include the oncologists’ familiarity and comfort 
with making changes to non-cancer medications, the need for communication and 
coordination with other providers, the patient or family member's reluctance to change 
medication, and, of course, the lack of evidence of benefit or harm of deprescribing in this 
population.
One approach to optimizing the prescribing and de-prescribing process is through utilization 
of pharmacists as part of the healthcare delivery model for inter-professional, team-based 
care.41 The Institute of Medicine recognizes the significant role played by pharmacists in the 
areas of medication therapy management and medication safety, as well as the value of 
pharmacist–physician collaboration in patient care.64-66 Pharmacists have the professional 
education, training, skills, and medication use expertise to employ evidence-based medicine 
which is crucial for this complex population that takes multiple medications. Teams led by 
pharmacists to identify, prevent, and resolve medication related problems and promote the 
correct use of medications may improve the likelihood that patients receive appropriate 
pharmaceutical care.7 Thus, there is potential for pharmacists to play an important role as a 
member of the inter-professional team.
CONCLUSIONS
In summary, there is a need for validated methods to define polypharmacy and to incorporate 
assessment and evaluation as a standard part of GA for older adults with cancer. While there 
are many acceptable definitions of polypharmacy, GA that includes screening for harmful 
medication use may require a simplified approach, to be able to consistently define the 
prevalence and impact of the problem and to design interventions. An increased number of 
medications that a patient is regularly taking is the most significant independent predictor of 
harm,62 both in general geriatric and in geriatric oncology populations. Once polypharmacy 
has been screened, the next step is to use a combination of tools designed to identify harmful 
medication use, such as the Beers and STOPP criteria, the MAI, as well as a review for high 
risk drugs. The Beers, STOPP, and MAI are considered viable options for use in clinical 
practice and may complement each other in their ability to identify harmful medications. 
Once harmful medication use has been identified, deprescribing interventions need to be 
initiated. Ultimately, to incorporate the assessment of polypharmacy into GA studies and 
interventions, a clear, simple definition of polypharmacy would be beneficial, and the 
methods of medication review and intervention need to be clearly described and developed 
within the field to improve replicability of such studies.
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Box. Steps to Deprescribe62
1) Reconcile all medications and consider their indications.
2) Consider overall risk of harm when considering the intensity of 
deprescribing intervention.
3) Assess each drug in terms of current or future benefit in relation to current 
or future harm.
4) Prioritize drugs for deprescribing, giving preference to those that have the 
most unfavorable risk/benefit ratio and least likelihood of withdrawal 
symptoms.
5) Implement a discontinuation plan and monitor for improvement or adverse 
effects as the result of deprescribing.
(Adapted from Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. 
Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 
2015;175(5):827-34.)
Sharma et al. Page 13
J Geriatr Oncol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sharma et al. Page 14
Table 1
Polypharmacy and Association with Outcomes in Geriatric Oncology
Study Population Definition of Polypharmacy Patients Meeting 
Polypharmacy 
Criteria
Outcomes
N %
Caillet et al. 
201135
375 patients ≥70 years with 
solid tumors in a GA 
intervention; 54.6% had 
metastatic disease
≥5 oral medications daily 242 67% Not associated with a change in 
cancer treatment plan
Parks et al. 
201536
47 women ≥70 years with 
early stage, operable breast 
cancer
≥4 daily medications 27 59% Associated with non-surgical 
treatment of cancer (p=0.002)
de Glas et al. 
201331
3179 women ≥65 years who 
underwent surgery for breast 
cancer (all stages)
≥ 5 different types of medication 428 14% Associated with the risk of 
postoperative complications 
OR 1.84, 95% confidence 
interval (CI) 1.46-2.32
Badgwell et al. 
201332
111 patients ≥65 years 
undergoing abdominal surgery 
for types of cancer, primarily 
GI
Use of ≥ 5 medications 53 48% Increased length of stay OR 
2.45, 95% CI 1.09-5.49
Hamaker et al. 
201433
73 women ≥65 years with 
metastatic breast cancer 
receiving first-line single-
agent palliative chemotherapy
Use of ≥ 5 medications 37 51% Associated with grade 3-4 
chemotherapy-related toxicity 
Unadjusted OR 6.38, 95% CI 
1.99-23.47
Freyer et al. 
200537
83 women >70 years with 
Stage III/IV ovarian cancer
≥ 6 daily medications 7 8% Lower overall survival 
(p=0.04) for those with 
polypharmacy
Kim et al. 
201434
98 patients ≥65 years 
receiving palliative 
chemotherapy (multiple 
cancer sites included)
>6 medications 39 40% No association with early 
discontinuation of palliative 
chemotherapy
Turner et al. 
201429
385 patients ≥ 70 years seen 
in an outpatient oncology 
clinic (multiple cancer sites 
included)
Use of ≥ 5 regular medications 221 57% Associated with impaired 
physical function (OR 1.13, 
95% CI 1.06-1.20) and being 
frail (OR 4.48, 95% CI 
1.90-10.54) and pre-frail (OR 
2.35, 95% CI 1.43-3.86)
Senel et al. 
201538
213 patients, mean age 60.3 
years, in an inpatient palliative 
care unit (multiple cancer sites 
included)
Use of >3 medications 111 52% Associated with incident 
delirium in univariate analysis 
(p<0.05)
Elliot et al. 
201430
150 patients >60 years of age, 
with acute myelogenous 
leukemia (AML)
Use of ≥ 4 medications 78 52% Associated with 30-day 
mortality in adjusted analysis 
(OR 9.98, 95% CI 1.18-84.13). 
Lower odds of achieving 
remission (OR 0.20, 95% CL 
0.06-0.65)
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Table 2
Interventions for Polypharmacy in Geriatric Assessment Studies
Study Definition of Polypharmacy Interventions Outcome
Aparicio et al. 
201067
1 anticoagulant or 2 cardiovascular or 2 
psychotropic medications or ≥10 
medications
Geriatricians proposed non-
oncologic treatment adaptation
CGA led to an adaptation of the non-
oncological treatment in 15 (72%) and of 
the social care in 8 (38%) patients, but 
never modified the oncological strategy
Caillet et al. 
201135
Concurrent use of >= 5 medications Geriatricians proposed change in 
prescribed medication
Functional status assessed by the ADL 
score and malnutrition were 
independently associated with changes in 
cancer treatment
Horgan et al. 
201268
-- Geriatric oncology service made 
recommendations on medication 
change
Previously unidentified medical problems 
were identified in 70% of patients
Kalsi et al. 
201561
Concurrent use of >= 5 medications Intervention to reduce 
unnecessary medications such as 
adjustment of antihypertensive 
medications in over or 
undertreated patients
Geriatrician-led CGA interventions were 
associated with improved chemotherapy 
tolerance
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